< Back to Results
Lung (Small Cell)
A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung CarcinomaUnique Dataset IDLungSm_EliLill_2011_287ClinicalTrial.gov IDNCT01439568
Clinical Trial Title
A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma
Trial Summary and Conditions
The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in patients with extensive-stage disease small cell lung cancer (SCLC)
Data files include raw data on safety, efficacy, demographics, etc. for all study subjects
The primary objective was to compare the progression-free survival (PFS) between treatment arms. Secondary objectives were OS, overall response rate (ORR), duration of overall response (DOR), and safety.
Primary Outcome Measures : 1. Progression Free Survival [ Time Frame: Baseline to measured progressive disease or date of death from any cause (estimate 2 years) ] Secondary Outcome Measures : 1. Number of participants achieving an objective Tumor response, (Objective Response Rate) [ Time Frame: Baseline to date of tumor response or measured progressive disease or date of death
To gain access to the data and analytic tools click here.
PROTOCOL: Lilly Protocol LY2510924_CXAC.pdf
CRF: Lilly CRF LY2510924_CXAC.pdf
DATA DICTIONARY: Proc Contents Data Dictionary.docx
DATA (COMPARATOR ARM): Lilly data LY2510924_CXAC.zip